Mamot, Christoph <br/><br/>
EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.  [electronic resource] 

 -  Journal of drug targeting  May 2006 
 - 215-23 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1061-186X 
<br/><br/><label>Standard No.: </label>10.1080/10611860600691049  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--administration & dosage<br/>Caco-2 Cells<br/>Cell Line, Tumor<br/>Cetuximab<br/>Colorectal Neoplasms--metabolism<br/>Doxorubicin--administration & dosage<br/>Drug Delivery Systems<br/>ErbB Receptors--immunology<br/>Humans<br/>Immunoglobulin Fab Fragments--administration & dosage<br/>Liposomes--administration & dosage